Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2025)
Keros Therapeutics (KROS) posted Return on Capital Employed of 12.99% for Q4 2025, up 116.41% on a QoQ basis from 6.0% in Q3 2025, and up 4997.0% year-over-year from 0.25% in Q4 2024.
Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2025) Analysis & Trends
Keros Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 12.99% for Q4 2025.
- Quarterly Return on Capital Employed rose 4997.0% year-over-year to 12.99% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 12.99% (up 4997.0% YoY) and the FY2025 annual result came in at 14.8%, up 6009.0% from the prior year.
- Return on Capital Employed was 12.99% for Q4 2025 at Keros Therapeutics, up from 6.0% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 12.99% in Q4 2025 and bottomed at 52.49% in Q4 2023.
- A 5-year average of 28.5% and a median of 37.04% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 1920 bps — and 2025, when it surged 4997 bps.
- Keros Therapeutics' Return on Capital Employed stood at 24.43% in 2021, then tumbled by 79 bps to 43.63% in 2022, then declined by 20 bps to 52.49% in 2023, then climbed by 30 bps to 36.98% in 2024, then surged by 135 bps to 12.99% in 2025.
- Business Quant data shows KROS's Return on Capital Employed at 12.99% in Q4 2025, 6.0% in Q3 2025, and 0.04% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Keros Therapeutics | 377.42 Mn | 90.02 Mn | - | 12.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 12.99% |
| Sep 30, 2025 | 6.00% |
| Jun 30, 2025 | 0.04% |
| Mar 31, 2025 | -1.56% |
| Dec 31, 2024 | -36.98% |
| Sep 30, 2024 | -41.80% |
| Jun 30, 2024 | -42.00% |
| Mar 31, 2024 | -43.88% |
| Dec 31, 2023 | -52.49% |
| Sep 30, 2023 | -47.89% |
| Jun 30, 2023 | -39.56% |
| Mar 31, 2023 | -39.23% |
| Dec 31, 2022 | -43.63% |
| Sep 30, 2022 | -38.45% |
| Jun 30, 2022 | -37.09% |
| Mar 31, 2022 | -27.72% |
| Dec 31, 2021 | -24.43% |
| Sep 30, 2021 | -28.71% |
| Jun 30, 2021 | -23.27% |
| Mar 31, 2021 | -20.39% |